Nurix Therapeutics Income Statement (2019-2025) | NRIX

Income Statement Aug2019 Nov2019 Feb2020 May2020 Aug2020 Nov2020 Feb2021 May2021 Aug2021 Nov2021 Feb2022 May2022 Aug2022 Nov2022 Feb2023 May2023 Aug2023 Nov2023 Feb2024 May2024 Aug2024 Nov2024 Feb2025 May2025 Aug2025
Revenue & cost
Revenue 10.58M1.86M2.86M4.18M4.08M6.69M5.01M7.09M10.25M7.40M9.62M11.43M10.79M6.78M12.69M30.68M18.47M15.16M16.59M12.09M12.59M13.28M18.45M44.06M7.89M
Operating items
Research & Development 11.01M12.82M12.97M14.14M18.94M20.45M23.00M25.99M30.91M36.53M43.14M47.49M47.76M46.11M45.82M45.76M47.86M49.71M50.01M48.92M55.48M67.22M69.66M78.10M86.12M
Selling, General & Administrative 2.18M2.60M2.45M3.27M4.34M6.25M6.53M7.51M8.34M8.82M9.23M9.65M9.75M9.37M9.82M11.68M10.62M10.78M11.80M11.71M11.72M10.72M11.65M14.28M13.16M
Operating Expenses 13.19M15.43M15.42M17.41M23.28M26.70M29.53M33.51M39.25M45.35M52.37M57.15M57.51M55.47M55.64M57.44M58.48M60.49M61.80M60.63M67.20M77.94M81.32M92.38M99.28M
Operating Income -2.61M-13.56M-12.55M-13.23M-19.19M-20.01M-24.52M-26.41M-29.00M-37.95M-42.74M-45.72M-46.72M-48.69M-42.95M-26.77M-40.01M-45.33M-45.22M-48.54M-54.61M-64.66M-62.86M-48.32M-91.39M
EBIT -2.61M-13.56M-12.55M-13.23M-19.19M-20.01M-24.52M-26.41M-29.00M-37.95M-42.74M-45.72M-46.72M-48.69M-42.95M-26.77M-40.01M-45.33M-45.22M-48.54M-54.61M-64.66M-62.86M-48.32M-91.39M
Non-operating items
Interest & Investment Income 0.20M0.26M0.17M0.22M0.68M0.14M0.32M0.17M0.04M0.29M0.21M0.31M1.01M1.97M2.22M2.49M3.03M3.38M3.79M4.08M5.74M6.12M6.51M5.62M4.96M
Net income details
EBT -2.42M-13.31M-12.38M-13.01M-18.52M-19.87M-24.20M-26.24M-28.96M-37.66M-42.53M-45.40M-45.71M-46.72M-40.73M-24.28M-36.98M-41.96M-41.43M-44.46M-48.87M-58.54M-56.35M-42.70M-86.42M
Tax Provisions 0.01M0.21M0.01M-20.59M0.02M0.07M0.14M-0.12M0.03M0.09M0.09M0.08M0.01M0.76M
Profit After Tax -2.43M-13.52M-12.39M7.58M-18.52M-19.91M-24.27M-26.38M-28.84M-37.70M-42.53M-45.40M-45.71M-46.72M-40.73M-24.28M-36.98M-41.96M-41.52M-44.55M-48.96M-58.55M-56.35M-43.46M-86.42M
Income from Continuing Operations -2.43M-13.52M-12.39M7.58M-18.52M-19.90M-24.27M-26.38M-28.84M-37.69M-42.53M-45.40M-45.71M-46.72M-40.73M-24.28M-36.98M-41.96M-41.52M-44.55M-48.96M-58.55M-56.35M-43.46M-86.42M
Consolidated Net Income -2.43M-13.52M-12.39M7.58M-18.52M-19.90M-24.27M-26.38M-28.84M-37.69M-42.53M-45.40M-45.71M-46.72M-40.73M-24.28M-36.98M-41.96M-41.52M-44.55M-48.96M-58.55M-56.35M-43.46M-86.42M
Income towards Parent Company -2.43M-13.52M-12.39M7.58M-18.52M-19.90M-24.27M-26.38M-28.84M-37.69M-42.53M-45.40M-45.71M-46.72M-40.73M-24.28M-36.98M-41.96M-41.52M-44.55M-48.96M-58.55M-56.35M-43.46M-86.42M
Net Income towards Common Stockholders -2.43M-13.52M-12.39M7.58M-18.52M-19.90M-24.27M-26.38M-28.84M-37.69M-42.53M-45.40M-45.71M-46.72M-40.73M-24.28M-36.98M-41.96M-41.52M-44.55M-48.96M-58.55M-56.35M-43.46M-86.42M
Additional items
EPS (Basic) -0.66-3.55-3.500.20-1.09-0.51-0.63-0.60-0.65-0.85-0.95-1.01-0.90-0.86-0.75-0.45-0.68-0.77-0.76-0.71-0.67-0.75-0.67-0.52-1.03
EPS (Weighted Average and Diluted) -1.32-0.63-0.65-0.85-0.95-1.01-0.90-0.86-0.75-0.45-0.68-0.77-0.76-0.71-0.67-0.75-0.67-0.52-1.03
Shares Outstanding (Weighted Average) 37.04M37.04M37.04M38.86M38.86M38.91M44.35M44.43M44.61M44.74M44.95M47.04M47.27M47.27M47.45M48.20M48.50M48.89M64.41M64.41M70.84M75.89M76.24M76.45M
Shares Outstanding (Diluted Average) 43.80M44.37M42.90M44.69M44.90M50.87M48.61M54.03M54.26M54.39M54.34M54.90M62.38M72.78M67.12M83.56M83.88M84.16M
EBITDA -2.61M-13.56M-12.55M-13.23M-19.19M-20.01M-24.52M-26.41M-29.00M-37.95M-42.74M-45.72M-46.72M-48.69M-42.95M-26.77M-40.01M-45.33M-45.22M-48.54M-54.61M-64.66M-62.86M-48.32M-91.39M
Shares Outstanding 3.52M3.60M3.67M3.79M38.85M38.86M39.12M44.40M44.56M44.66M44.85M45.04M47.15M47.17M47.44M47.63M48.50M48.72M49.14M64.36M67.08M75.87M76.23M76.43M76.87M
Tax Rate 0.42